semaglutide in heart failure patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for or all-cause mortality vs sitagliptin, but tirzepatide offered no additional benefit over semaglutide. https://ja.ma/3JO2SQc Semaglutide cardiovascular outcomes align more

Low doses may not suppress your appetite The starting dosage of semaglutide is very low to reduce the risk of side effects and may not be sufficient to suppress appetite effectively for some people

"There's some data to suggest that a dose tapering strategy, so where you minimize or lower the doses over time might prevent weight regain."

The numbers come from the STEP 1 trial of semaglutide 2.4 mg, which is the most rigorous long-term data available, with real-world variation noted where it matters

Intersection analysis using a Venn diagram of RA-related, gut microbiota-related, and ferroptosis-related genes identified, for the first time, 16 genes potentially mediating RA pathology and involved in gut microbiota metabolism and ferroptosis (EGFR, MAPK8, NQO1, APOE, TGFB1, LCN2, HMOX1, NR1H4, PLIN2, PTGS2, CDKN1A, IL6, FFAR2, GPX3, JUN, and MYC)